ABOUT US

ZHONGCHAO INC. (NasdaqCM: ZCMD)

Zhongchao Inc. a holding company incorporated under the laws of the Cayman Islands, through its variable interest entity and subsidiaries, provides healthcare information, education, and training services to healthcare professionals and the public in China. The Company commenced its operation, through Zhongchao Shanghai, in August 2012 with a vision to offer a wide range of accessible and immediate healthcare information and continuous learning and training opportunities for Chinese healthcare professionals.

More

Stock Chart
News
  • 01 Zhongchao Inc.’s Operating Entity, Chongqing Xinjiang Pharmaceutical Co.,Ltd. Obtained Pharmaceutical Trade and Medical Device Operation Licenses,Ready to Enter Into Pharmaceuticals Circulation Market

    Shanghai, China, November 3, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements, Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Xinjiang Pharmaceutical”) has obtained a series of pharmaceutical related licenses, which lay a solid foundation for Zhongchao to develop pharmaceutical services and expand to the pharmaceutical market. The Company believes that the operation of Xinjiang Pharmaceutical will further strengthen the upgraded “Medical-Pharmaceutical-Patient” model.

  • 02 Zhongchao Inc. Establishes Chongqing Xinjiang Pharmaceutical Co., Ltd. to Improve Patient Access to Medications

    SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang Pharmaceutical") which mainly engages in pharmaceutical import and export trade, OME (original equipment manufacturer) production, medical consumables operation, and pharmaceutical internet services. Zhongchao expects to further improve and complement its business model of "Medical-Pharmaceutical-Patient" as Xinjiang Pharmaceutical plays an important role in supplying quality medications for patients.

  • 03 Zhongchao Inc. Establishes Zhixun Internet Hospital to Provide Patient with Management Services Focusing on the Oncology and Other Major Diseases

    Shanghai, China, September 15, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced that its subsidiary, Zhixun Internet Hospital (Liaoning) Co., Ltd., launched Zhixun Internet Hospital to provide standardized Internet healthcare services for patients with oncology or other major diseases. It is another important step for Zhongchao to further improve its patient management services in the field of oncology and major diseases.

  • 04 Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management

    SHANGHAI, Sept 1, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated experiences in medical education and innovation, and extensive resources with medical professionals and pharmaceuticals, Zhongchao is well positioned to become a platform that provides patients with major disease management services.